fenofibrate has been researched along with Atheroma in 3 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "The STAFENO trial is a prospective, randomized, open-label, multi-center trial to compare the effect of statin plus fenofibrate with statin alone on the reduction and stabilization of plaque in non-diabetic, combined dyslipidemia patients with non-intervened, intermediate coronary artery disease (CAD) using virtual histology-intravascular ultrasound at 12 months." | 9.34 | Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFE ( Bae, JH; Han, SH; Hong, YJ; Jang, AY; Kim, SH; Kim, SW; Kwon, TG; Lee, SY, 2020) |
| "The STAFENO trial is a prospective, randomized, open-label, multi-center trial to compare the effect of statin plus fenofibrate with statin alone on the reduction and stabilization of plaque in non-diabetic, combined dyslipidemia patients with non-intervened, intermediate coronary artery disease (CAD) using virtual histology-intravascular ultrasound at 12 months." | 5.34 | Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFE ( Bae, JH; Han, SH; Hong, YJ; Jang, AY; Kim, SH; Kim, SW; Kwon, TG; Lee, SY, 2020) |
| " In this study, we examined molecular mechanisms that explain differential effects of a PPARα agonist (fenofibrate) and a PPARγ agonist (rosiglitazone) on macrophages during obesity-induced atherogenesis." | 3.79 | PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression. ( Arnould, T; Geeraert, B; Holvoet, P; Hulsmans, M; Tsatsanis, C, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kwon, TG | 1 |
| Jang, AY | 1 |
| Kim, SW | 1 |
| Hong, YJ | 1 |
| Bae, JH | 1 |
| Lee, SY | 1 |
| Kim, SH | 1 |
| Han, SH | 1 |
| Garg, G | 1 |
| Patil, A | 1 |
| Singh, J | 1 |
| Kaushik, N | 1 |
| Praksah, A | 1 |
| Pal, A | 1 |
| Chakrabarti, A | 1 |
| Hulsmans, M | 1 |
| Geeraert, B | 1 |
| Arnould, T | 1 |
| Tsatsanis, C | 1 |
| Holvoet, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Comparative Analysis of the Effects on Plaque Volume and Tissue Characteristics Between Combined Therapy With STAatin Plus FENOfibrate and Statin Alone in Mild to Moderate, Non- Intervened Coronary Artery Stenosis (STAFENO Trial)[NCT02232360] | Phase 4 | 106 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for fenofibrate and Atheroma
| Article | Year |
|---|---|
Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFE
Topics: Adult; Aged; Aged, 80 and over; Coronary Artery Disease; Drug Therapy, Combination; Dyslipidemias; F | 2020 |
2 other studies available for fenofibrate and Atheroma
| Article | Year |
|---|---|
Pharmacological evaluation of Convolvulus pluricaulis as hypolipidaemic agent in Triton WR-1339-induced hyperlipidaemia in rats.
Topics: Animals; Atherosclerosis; Biomarkers; Convolvulus; Disease Models, Animal; Female; Fenofibrate; Hype | 2018 |
PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.
Topics: Adipocytes; Adiponectin; Animals; Chemokine CCL2; Diet, High-Fat; Fenofibrate; Inflammation; Insulin | 2013 |